من السبت الى الخميس (8:00AM-2:00PM)
تواصل معنا : +9647716699096







  • م. م. لبنى زهير عبد الكريم
  • Lubna Zuhair
  • تدريسي : كلية الصيدلة
  • Teaching : University Of Pharmacy
  • ماجستير صيدلة / ادوية و سموم
  • Master's degree in pharmacology and toxicology
  • lubna.zuhair@bauc14.edu.iq
  • lubnazuhear1989@gmail.com
  • المقررات المكلف بها

    المقررات المكلف بها - 1
    القسم المرحلة الفصل رمز المقرر الوحدات توصيف المقرر
    كلية الصيدلة المرحلة الاولى فصل اول PHBI1MT 1 Medical Terminology

    المحاضرات الالكترونية

    المحاضرات الالكترونية - 6
    العام المقرر القسم المرحلة المحاضرة
    2024-2025 Medical Terminology كلية الصيدلة المرحلة الاولى Digestive system - lecture 6
    2024-2025 Medical Terminology كلية الصيدلة المرحلة الاولى Urinary system - lecture 5
    2024-2025 Medical Terminology كلية الصيدلة المرحلة الاولى Respiratory system - lecture 4
    2024-2025 Medical Terminology كلية الصيدلة المرحلة الاولى Integumentary system - lecture 3
    2024-2025 Medical Terminology كلية الصيدلة المرحلة الاولى Medical terminology- lecture 2
    2024-2025 Medical Terminology كلية الصيدلة المرحلة الاولى Medical terminology- lecture. 1

    البحوث

    2021 systematic reviews in pharmacy journal
    "ABSTRACT Doxorubicin (DOX) is a powerful anticancer agent with sever cardiotoxic side effect which limits the clinical use. Metformin (MET) is antihyperglycemic drug with potential cardioprotective effect via AMP-activated protein kinase (AMPK) (increases fatty acid oxidation, decreases the production of ROS, maintaining energy homeostasis and apoptosis). Metabolomics technology deals with systematic study of chemical fingerprints of metabolite profiles. Different metabolic processes can be identified which will give information of any change in the metabolic profile of tissues as well as of biofluids after drug administration. This research designed to investigate MET cardioprotective effect against acute cardiotoxicity induced by DOX using metabolomics technology. Methods: Twenty four adult male wistar rats divided into four groups (6 animals each): control group (saline, i.p.); MET group (300mg/kg/day for 7dayes) by gavage; DOX group (20 mg/kg,i.p.) for acute induction of cardiotoxicity; Met + DOX group received DOX (20mg/kg i.p.) and Met (300 mg/kg/day, for 7 days, starting five days prior to DOX treatment) orally with gavage. Assessment of heart tissue metabolomics, serum MDA and GSH in addition to trichrome stain. Results: The results showed that pretreatment with MET (MET+DOX) significantly (p<0.05) reduced the level of acetic acid, cholesterol, palmitic acid, phosphoric acid, pyruvic acid, stearic acid, glucose, myo-inositol, alanine, lysine, and proline. Also, the level of arachidonic acid, hydroxybutyric acid, lactic acid, linoleic acid, oleic acid, oxalic acid, propionic acid, and galactose reduced after pretreatment with MET (MET+DOX). Additionally, (MET +DOX) resulted in significant decrease (p<0.05) in the level of serum MDA as well as significant (p<0.05) increase in serum GSH levels. In addition to significantly decreased collagen fiber production. Conclusion: It can be concluded that MET improved cardiac structure and function, as well as the metabolism of DOX-induced cardiotoxicity group, as it reduced the level of biomarkers associated with cardiotoxicity including (arachidonic, linoleic, oleic, acetic, stearic) acids, cholesterol ,leucine, glucose, mannose, myoinositol as well as hydroxybutyric acid. This indicates that MET induced a metabolic alterations, including the promotion of glycogenolysis, glycolysis, amino acid utilization and antioxidation. Additionally, MET improving energy metabolism and attenuating oxidative stress through suppression of serum MDA and increase the level of GSH as well as decrease fibrosis and structural changes."




    En